Journal of Hypertension · 1998 · 49 citations · 31 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyExperimental PharmacologyPharmacodynamicsBlood Pressure ControlBlood Pressure RegulationCardiovascular PharmacodynamicsCardiovascular PharmacologyHypertension ControlHypertension PharmacotherapyAntihypertensive Drug TherapyAntihypertensive InteractionsAntihypertensive PharmacologyAntihypertensive TreatmentBlood PressureHeart RateHypertensive Drug ResponsePharmacological Interaction In Hypertension
OBJECTIVE: To investigate the chronic effects of combined administration of an angiotensin II receptor antagonist (valsartan) and an angiotensin converting enzyme inhibitor (benazeprilat) on blood pressure and heart rate in conscious telemetered spontaneously hypertensive rats. METHODS: Blood pressure and heart rate were monitored (by radiotelemetry) during 2-week infusions of 0.5-10 mg/kg valsartan per day and 0.5-10 mg/kg benazeprilat per day, alone or in combination, into conscious spontaneously hypertensive rats. Also, responses of blood pressure in conscious spontaneously hypertensive rats to exogenous angiotensin I and II were determined. RESULTS: Synergistic antihypertensive effects were observed when valsartan and benazeprilat were coadministered at submaximal monotherapy doses in the range 0.5-1.5 mg/kg per day. For all combination groups, the area over the curve (mmHg x days) for lowering of blood pressure was significantly greater (synergy) than that predicted from the sum of the monotherapy responses. Combination therapy abrogated pressor responses to angiotensin I more effectively than did comparable doses of the monotherapies. CONCLUSIONS: These results demonstrate that combination therapy aimed at interrupting operation of the renin-angiotensin system simultaneously at multiple sites can prevent the partial escape which occurs during chronic angiotensin converting enzyme inhibitor monotherapy. Furthermore, multiple-site intervention results in a more efficacious antihypertensive response than that achieved with high doses of the individual monotherapies.
31
Leoluca Criscione, Marc de Gasparo, Peter Bühlmayer et al. · British Journal of Pharmacology · 1993 · 251 citations · Full text
Determinants of angiotensin II generation during converting enzyme inhibition.
Lucienne Juillerat, J. Nussberger, Joël Ménard et al. · Hypertension · 1990 · 214 citations · Full text
True versus immunoreactive angiotensin II in human plasma.
J. Nussberger, D. B. Brunner, Bernard Waeber et al. · Hypertension · 1985 · 187 citations · Full text